<DOC>
	<DOC>NCT00888693</DOC>
	<brief_summary>Evaluate the safety, tolerability and pharmacokinetics of ABT-288 in order to determine the maximum tolerated dose of ABT-288 in stable schizophrenic volunteers receiving treatment with an atypical antipsychotic.</brief_summary>
	<brief_title>A Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-288 in Stable Subjects With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Subject has signed informed consent; Current DSMIVTR diagnosis of schizophrenia; Clinically stable on the same single secondgeneration antipsychotic for the past 8 weeks; Meets studyspecific PANSS criteria; Willing and able to cooperate with cognitive testing Females are not pregnant, not breastfeeding; Females are postmenopausal or surgically sterile or practicing birth control; Males are surgically sterile or agree to be sexually inactive or use barrier method of birth control Subject has a substance dependence disorder that has not been in sustained remission for at least 1 year; Diagnosis of schizoaffective disorder; Bipolar disorder, manic episode, dementia, OCD, or druginduced psychosis or current major depressive disorder; Diagnoses with mental retardation; acute psychosis hospitalization within past 6 months; Current clozapine treatment; suicidal ideation or behavior; BMI of 39 or greater; current homicidal or violent ideation; Medical or CNS condition other than schizophrenia that could affect cognitive performance or testing; relevant drug sensitivity or allergy; positive urine screen for alcohol or drugs of abuse; Positive hepatitis or HIV test result; Recent clinically significant illness/infection or surgery; Recent blood product transfusion, donation or loss of 5 mL/kg of blood; Visual, hearing or communication disability</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>